Preclinical models play a vital role in understanding the potency, efficacy and safety of new pharmaceutical products, allowing developers to make timely decisions on the progression of drug candidates.Given their importance for de-risking development programs, it's essential preclinical models are as translational to human pathology as possible. After all, unreliable information on the efficacy or safety of candidates can lead to ineffective or potentially unsafe molecules being progressed towards the clinical stage, with associated risk to investment and, most importantly, human health. Improving the quality of information these models provide is therefore an important goal in drug development across many therapeutic areas.